Stocks to Buy based on the Best Stock Market Research
This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA
Aequus Pharma (AQS.V) (AQSZF)
Market-Cap: $11 M
Shares out: 54 Million
Presentation August 2016
Marketed Products :
Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)
•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.
Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017 < Licensed from Supernus Pharma (SUPN)
Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017 < Licensed from Supernus Pharma (SUPN)
NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)
AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.
Interview with Ceo Doug Janzen
James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?
Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.
James West: Sure. Have you built a pharmaceutical company before, Doug?
Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.
Replies to This Discussion
Got a great Reply by Ceo Janzen ..this unknown Goldmine should be at $2+ right now ...Bought my shares back in last few days .
firstname.lastname@example.org Jan 6 at 10:13 PM
Hello XXX and Happy New Year… Thanks for your email.
The share price has been a negative surprise over the last few months. The business is going well, sales are growing and we expect additional commercial deals for revenue generating products to be announced this quarter. We also are about to start the second clinical trial for our transdermal Abilify product this month and our partner Corium has begun work on the next two transdermal programs. We have a lot of confidence in the business model and expect big things in 2017. Tax loss selling hurt the share price in December but in general the share price has been weaker than I expected. I personally bought 1million shares in 2016 and plan to buy more once I come out of a trading blackout. Our goal is to be profitable before the end of 2017 which at that point will remove the requirement for going to investors for financings.
Happy to chat if you would like to have a phone call…
Best, Doug Janzen Chairman and CEO / CoFounder Aequus Pharmaceuticals
AQSZF is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this stock must be the cheapest Biotech out there .Stock should be at minimum $2+ right now .
[b]File for CDN approval of Topiramate XR and Oxcarbazepine XR
Operational profitability estimated in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018[/b]
Great Video shows again the mega potential here
Great News out today ..Cannabinoid Patch =HUGE Potential
VANCOUVER, BC--(Marketwired - March 02, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company") announced today that through a previously announced Research Service Contract with Transdermal Research Pharma Lab ("TRPL") it has entered into a binding term sheet (the "Term Sheet") to acquire an exclusive world-wide license to a transdermal patch containing cannabinoids, for the use in epilepsy, Multiple Sclerosis (MS), and certain other neurological disorders.
GREAT News out , this product alone could bring as much as $200 million in annual revenue and this unknown goldmine is value at laughable $14 million .This one has reallly 20 bagger potential if everything goes well .GL
Aequus Pharmaceuticals : Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
The Abilify brand and generic tablets had U.S. sales of approximately $3.1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health*.
MUST WATCH to realize the MEGA MONSTER POTENTIAL HERE